Pacira BioSciences, Inc. (PCRX) Financial Ratios
18 years of historical data (2008–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↓
9.44
↓-84% vs avg
5yr avg: 59.38
30Y Low11.8·High71.7
P/FCF
↓
6.43
↓-58% vs avg
5yr avg: 15.19
30Y Low4.9·High137.5
P/B Ratio
↓
1.45
↓-33% vs avg
5yr avg: 2.18
30Y Low1.1·High46.2
ROE
↓
1.0%
↓+107% vs avg
5yr avg: 0.5%
30Y Low-119%·High30%
Debt/EBITDA
↓
3.65
↓-87% vs avg
5yr avg: 27.96
30Y Low3.6·High21.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PCRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Pacira BioSciences, Inc. trades at 139.6x earnings, 47% above its 5-year average of 94.7x, sitting at the 80th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 531%. On a free-cash-flow basis, the stock trades at 6.4x P/FCF, 58% below the 5-year average of 15.2x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $878M | $1.2B | $871M | $1.8B | $1.8B | $2.7B | $2.6B | $1.9B | $1.8B | $1.8B | $1.2B |
| Enterprise Value | $1.2B | $1.5B | $1.2B | $2.2B | $2.5B | $3.3B | $3.1B | $2.2B | $1.9B | $2.0B | $1.3B |
| P/E Ratio → | 139.56 | 161.75 | — | 37.91 | 113.56 | 65.40 | 17.97 | — | — | — | — |
| P/S Ratio | 1.21 | 1.60 | 1.24 | 2.60 | 2.69 | 5.07 | 6.08 | 4.47 | 5.22 | 6.34 | 4.35 |
| P/B Ratio | 1.45 | 1.68 | 1.12 | 2.02 | 2.32 | 3.76 | 4.22 | 5.30 | 5.48 | 6.50 | 5.49 |
| P/FCF | 6.43 | 8.53 | 4.87 | 12.57 | 15.60 | 34.38 | 66.63 | 31.15 | 51.23 | — | 137.55 |
| P/OCF | 5.78 | 7.67 | 4.60 | 11.34 | 12.37 | 21.84 | 33.93 | 26.67 | 36.01 | 102.17 | 35.95 |
P/E links to full P/E history page with 30-year chart
PCRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Pacira BioSciences, Inc.'s enterprise value stands at 9.4x EBITDA, 84% below its 5-year average of 59.4x. The Healthcare sector median is 14.2x, placing the stock at a 34% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.01 | 1.76 | 3.24 | 3.68 | 6.07 | 7.11 | 5.12 | 5.69 | 7.12 | 4.62 |
| EV / EBITDA | 9.44 | 11.76 | 227.80 | 13.39 | 16.21 | 27.76 | 46.11 | 71.67 | 65.97 | — | — |
| EV / EBIT | 35.26 | 46.43 | — | 27.67 | 50.25 | 38.51 | 70.06 | 192.81 | 96.45 | — | — |
| EV / FCF | — | 10.69 | 6.90 | 15.68 | 21.32 | 41.19 | 77.87 | 35.69 | 55.84 | — | 145.87 |
PCRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Pacira BioSciences, Inc. earns an operating margin of 4.6%. Operating margins have compressed from 13.0% to 4.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 1.0% is modest. ROIC of 2.3% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.4% | 79.4% | 75.7% | 72.6% | 70.1% | 74.1% | 72.7% | 74.7% | 74.3% | 69.3% | 60.2% |
| Operating Margin | 4.6% | 4.6% | -10.5% | 13.0% | 9.0% | 16.6% | 10.8% | 2.5% | 4.7% | -8.7% | -11.6% |
| Net Profit Margin | 1.0% | 1.0% | -14.2% | 6.2% | 2.4% | 7.8% | 33.9% | -2.6% | -0.1% | -14.9% | -13.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 1.0% | 1.0% | -12.1% | 5.1% | 2.1% | 6.2% | 29.9% | -3.3% | -0.2% | -17.1% | -17.4% |
| ROA | 0.5% | 0.5% | -6.4% | 2.6% | 0.8% | 2.5% | 13.8% | -1.4% | -0.1% | -8.4% | -9.7% |
| ROIC | 2.3% | 2.3% | -4.5% | 4.8% | 3.3% | 5.8% | 4.1% | 1.4% | 2.4% | -4.7% | -10.5% |
| ROCE | 2.8% | 2.8% | -5.4% | 5.8% | 3.9% | 7.0% | 5.3% | 1.6% | 2.7% | -5.4% | -11.0% |
PCRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Pacira BioSciences, Inc. carries a Debt/EBITDA ratio of 3.7x, which is moderately leveraged (14% above the sector average of 3.2x). Net debt stands at $296M ($454M total debt minus $159M cash). Interest coverage of just 2.2x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.66 | 0.66 | 0.82 | 0.67 | 0.99 | 1.55 | 0.87 | 0.99 | 0.91 | 0.99 | 0.50 |
| Debt / EBITDA | 3.65 | 3.65 | 118.00 | 3.59 | 5.04 | 9.53 | 8.17 | 11.71 | 10.00 | — | — |
| Net Debt / Equity | — | 0.43 | 0.47 | 0.50 | 0.85 | 0.74 | 0.71 | 0.77 | 0.49 | 0.80 | 0.33 |
| Net Debt / EBITDA | 2.38 | 2.38 | 66.88 | 2.65 | 4.35 | 4.59 | 6.66 | 9.11 | 5.45 | — | — |
| Debt / FCF | — | 2.16 | 2.03 | 3.10 | 5.72 | 6.80 | 11.25 | 4.53 | 4.61 | — | 8.33 |
| Interest Coverage | 2.16 | 2.16 | -3.00 | 4.56 | 1.37 | 2.95 | 1.70 | 0.47 | 0.91 | -1.43 | -4.45 |
PCRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Pacira BioSciences, Inc.'s current ratio of 4.54x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.28x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 5.24x to 4.54x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.54 | 4.54 | 2.40 | 5.24 | 3.37 | 1.66 | 2.57 | 3.79 | 7.88 | 6.96 | 5.42 |
| Quick Ratio | 3.28 | 3.28 | 2.00 | 4.17 | 2.72 | 1.47 | 2.32 | 3.25 | 7.08 | 6.22 | 4.72 |
| Cash Ratio | 1.98 | 1.98 | 1.56 | 2.86 | 1.95 | 1.26 | 2.06 | 2.71 | 6.32 | 5.54 | 3.85 |
| Asset Turnover | — | 0.57 | 0.45 | 0.43 | 0.40 | 0.26 | 0.34 | 0.51 | 0.49 | 0.46 | 0.71 |
| Inventory Turnover | 0.98 | 0.98 | 1.36 | 1.77 | 2.07 | 1.42 | 1.81 | 1.83 | 1.79 | 2.12 | 3.52 |
| Days Sales Outstanding | — | 62.34 | 59.00 | 57.08 | 53.86 | 64.92 | 45.06 | 41.21 | 41.12 | 40.31 | 39.54 |
PCRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Pacira BioSciences, Inc. returns 16.9% to shareholders annually primarily through share buybacks. The earnings yield of 0.7% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.7% | 0.6% | — | 2.6% | 0.9% | 1.5% | 5.6% | — | — | — | — |
| FCF Yield | 15.6% | 11.7% | 20.5% | 8.0% | 6.4% | 2.9% | 1.5% | 3.2% | 2.0% | — | 0.7% |
| Buyback Yield | 16.9% | 12.7% | 2.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 16.9% | 12.7% | 2.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $45M | $46M | $52M | $47M | $46M | $44M | $42M | $41M | $40M | $37M |
Peer Comparison
Compare PCRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PCRXYou | $878M | 139.6 | 9.4 | 6.4 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 PRGO | $1B | -1.0 | 7.1 | 9.8 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 BHC | $2B | 11.1 | 6.3 | 1.8 | 60.9% | 21.3% | 588.2% | 8.2% | 6.1 |
 SUPN | $3B | -65.3 | 45.1 | 55.6 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 PAHC | $1B | 26.8 | 12.7 | 30.9 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 HALO | $8B | 26.8 | 11.2 | 12.6 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
 NKTR | $1B | -6.3 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 AVDL | $2B | -42.4 | — | — | 91.0% | -25.1% | -60.4% | -76.3% | — |
 MDT | $102B | 22.0 | 14.5 | 19.6 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 SYK | $118B | 36.6 | 21.2 | 27.5 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
 ZBH | $17B | 24.8 | 9.8 | 11.7 | 61.6% | 16.5% | 5.6% | 5.4% | 3.1 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 18 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
PCRX — Frequently Asked Questions
Quick answers to the most common questions about buying PCRX stock.
What is Pacira BioSciences, Inc.'s P/E ratio?
Pacira BioSciences, Inc.'s current P/E ratio is 139.6x. The historical average is 79.3x. This places it at the 80th percentile of its historical range.
What is Pacira BioSciences, Inc.'s EV/EBITDA?
Pacira BioSciences, Inc.'s current EV/EBITDA is 9.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 36.1x.
What is Pacira BioSciences, Inc.'s ROE?
Pacira BioSciences, Inc.'s return on equity (ROE) is 1.0%. The historical average is -21.2%.
Is PCRX stock overvalued?
Based on historical data, Pacira BioSciences, Inc. is trading at a P/E of 139.6x. This is at the 80th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Pacira BioSciences, Inc.'s profit margins?
Pacira BioSciences, Inc. has 79.4% gross margin and 4.6% operating margin.
How much debt does Pacira BioSciences, Inc. have?
Pacira BioSciences, Inc.'s Debt/EBITDA ratio is 3.7x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.